NO2023041I1 - Pegunigalsidase alfa - Google Patents

Pegunigalsidase alfa

Info

Publication number
NO2023041I1
NO2023041I1 NO2023041C NO2023041C NO2023041I1 NO 2023041 I1 NO2023041 I1 NO 2023041I1 NO 2023041 C NO2023041 C NO 2023041C NO 2023041 C NO2023041 C NO 2023041C NO 2023041 I1 NO2023041 I1 NO 2023041I1
Authority
NO
Norway
Prior art keywords
pegunigalsidase
alfa
pegunigalsidase alfa
Prior art date
Application number
NO2023041C
Other languages
English (en)
Norwegian (no)
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of NO2023041I1 publication Critical patent/NO2023041I1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
NO2023041C 2010-03-02 2023-11-01 Pegunigalsidase alfa NO2023041I1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
US201161434503P 2011-01-20 2011-01-20
US201161434499P 2011-01-20 2011-01-20

Publications (1)

Publication Number Publication Date
NO2023041I1 true NO2023041I1 (no) 2023-11-01

Family

ID=44121635

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2023041C NO2023041I1 (no) 2010-03-02 2023-11-01 Pegunigalsidase alfa

Country Status (23)

Country Link
EP (3) EP3088514B1 (enExample)
JP (2) JP5758920B2 (enExample)
KR (1) KR101928403B1 (enExample)
CN (1) CN102933707B (enExample)
AU (1) AU2011222452B2 (enExample)
BR (2) BR112012022029B1 (enExample)
CA (1) CA2791461C (enExample)
DK (1) DK2865751T3 (enExample)
ES (2) ES2606532T3 (enExample)
FI (1) FIC20230032I1 (enExample)
FR (1) FR23C1041I2 (enExample)
HR (1) HRP20200428T1 (enExample)
HU (2) HUE030959T2 (enExample)
IL (2) IL221741A (enExample)
IN (1) IN2012MN02262A (enExample)
NL (1) NL301249I2 (enExample)
NO (1) NO2023041I1 (enExample)
NZ (2) NZ602317A (enExample)
PL (1) PL2865751T3 (enExample)
SG (2) SG183558A1 (enExample)
SI (1) SI2865751T1 (enExample)
WO (1) WO2011107990A1 (enExample)
ZA (1) ZA201206725B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
BR112012022029B1 (pt) * 2010-03-02 2022-10-11 Protalix Ltd Estrutura de proteina multimérica, seu uso e processo para preparação da estrutura de proteína multimérica
ES2774190T3 (es) * 2011-01-20 2020-07-17 Protalix Ltd Composiciones de alfa-galactosidasa
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
KR102438885B1 (ko) 2014-12-22 2022-09-01 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
EP3271453B1 (en) 2015-03-17 2021-09-08 eleva GmbH Glycosylated lysosomal proteins, method of production and uses
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US12194079B2 (en) * 2017-01-05 2025-01-14 Protalix Ltd. Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase
CN110651043A (zh) * 2017-06-07 2020-01-03 天野酶制品株式会社 乳糖酶原料粉末和乳糖酶制剂
CN113544268A (zh) 2018-12-20 2021-10-22 科德克希思公司 人类α半乳糖苷酶变体
AR121457A1 (es) * 2020-02-28 2022-06-08 Codexis Inc VARIANTES DE a-GALACTOSIDASA HUMANA
EP4240423A1 (en) 2020-11-03 2023-09-13 Protalix Ltd. Modified uricase and uses thereof
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
CN116254287B (zh) * 2022-11-24 2024-06-04 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用
CN118243646B (zh) * 2024-04-24 2025-01-24 武汉简为医疗科技有限公司 一种乳糖不耐受检测试剂盒及其使用方法
JP7745040B1 (ja) * 2024-06-21 2025-09-26 デンカ株式会社 目的タンパク質の回収方法及び製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
DE69839563D1 (de) * 1997-09-05 2008-07-10 Altus Pharmaceuticals Inc Kohlenhydrat-vernetzte glykoproteinkristalle
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
WO2000059926A1 (en) * 1999-04-02 2000-10-12 Ajinomoto Co., Inc. Process for producing subunit peptide origintaing in polymer protein
AU2003235988A1 (en) 2002-05-15 2003-12-02 Agricultural Research Organization, The Volcani Center Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
WO2006108052A2 (en) * 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
AU2006316122A1 (en) * 2005-11-18 2007-05-24 Altif Laboratories Inc. Novel highly functional enzyme having modified substrate-specificity
WO2008075957A1 (en) 2006-12-21 2008-06-26 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (en) * 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
BRPI0815324A2 (pt) 2007-08-20 2015-07-14 Protalix Ltd "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
BR112012022029B1 (pt) * 2010-03-02 2022-10-11 Protalix Ltd Estrutura de proteina multimérica, seu uso e processo para preparação da estrutura de proteína multimérica

Also Published As

Publication number Publication date
IN2012MN02262A (enExample) 2015-06-12
NZ623294A (en) 2015-10-30
HK1180720A1 (en) 2013-10-25
DK2865751T3 (en) 2017-01-09
EP2865751A1 (en) 2015-04-29
CA2791461A1 (en) 2011-09-09
HUE030959T2 (en) 2017-06-28
HRP20200428T1 (hr) 2020-06-12
RU2012141651A (ru) 2014-04-10
PL2865751T3 (pl) 2017-03-31
ZA201206725B (en) 2013-06-26
NZ602317A (en) 2014-04-30
NL301249I2 (nl) 2023-12-14
EP2865751B1 (en) 2016-09-14
KR20130056216A (ko) 2013-05-29
BR112012022029A2 (pt) 2021-05-18
SG183558A1 (en) 2012-10-30
IL253249A (en) 2019-08-29
KR101928403B1 (ko) 2018-12-14
FR23C1041I2 (fr) 2024-08-02
HUS2300038I1 (hu) 2023-11-28
SG10201502609QA (en) 2015-05-28
EP3088514A1 (en) 2016-11-02
JP2014237694A (ja) 2014-12-18
EP3088514B1 (en) 2018-11-28
JP2013520986A (ja) 2013-06-10
CA2791461C (en) 2019-10-22
ES2708843T3 (es) 2019-04-11
BR112012022029B1 (pt) 2022-10-11
WO2011107990A1 (en) 2011-09-09
CN102933707A (zh) 2013-02-13
BR122014021216A2 (pt) 2021-06-01
IL221741A (en) 2017-07-31
RU2604795C2 (ru) 2016-12-10
JP5758920B2 (ja) 2015-08-05
CN102933707B (zh) 2015-09-30
FR23C1041I1 (enExample) 2023-12-29
EP2542675B1 (en) 2014-12-17
ES2606532T3 (es) 2017-03-24
JP5871999B2 (ja) 2016-03-01
SI2865751T1 (sl) 2017-01-31
IL253249B (en) 2020-08-31
NL301249I1 (enExample) 2023-11-08
FIC20230032I1 (fi) 2023-11-02
AU2011222452B2 (en) 2015-09-03
EP2542675A1 (en) 2013-01-09
AU2011222452A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
FIC20230032I1 (fi) Pegunigalsidaasi alfa
FIC20220051I1 (fi) Olipudaasi alfa
FIC20240027I1 (fi) efbemalenograstiimi alfa
DK3225404T3 (da) Fluidpatron
EP2578585A4 (en) Purinone derivative
BR112012028556A2 (pt) Indóis
DE102011100241A8 (de) Nitridhalbleiterbauteil
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
EP2553434A4 (en) FLUOROMETRIC PROBE
EP2568873A4 (en) VACUUM RETRACTOR
EP2529782A4 (en) INTRODUCER SLEEVE ASSEMBLY
EP2591235A4 (en) FUSION METAL WHEEL
DE112011104226A5 (de) Käfigmutter
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DE112011101226A5 (de) Linearwegmesssystem
DE112011102080A5 (de) Kupplungszentralausrücker
DK2539163T3 (da) Dækventil
DK2442899T3 (da) Rotorskive
DE102010038420A8 (de) Reinigungungsvorrichtung
NO2018032I1 (no) velmanase alfa
DE102011002623A8 (de) Ventilsteuerzeitversteller
EP2571003A4 (en) RISK CALCULATION APPARATUS
DE112011102711A5 (de) Hydrostataktor
DK2448659T3 (da) Rotorskive